Top Markets
Coin of the day
Moleculin Biotech, Inc. Moleculin Biotech, Inc.

Moleculin Biotech, Inc.

MBRX
Hisse Senetlerindeki Sıralama #35911
Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to... Moleculin Biotech, Inc. is a clinical-stage pharmaceutical company dedicated to advancing therapeutic candidates designed to combat highly aggressive cancers and viral infections. Their primary investigational drug, Annamycin, is currently undergoing Phase 1/2 clinical trials. These trials aim to assess its efficacy against acute myeloid leukemia (AML) that has relapsed or is resistant to prior therapies, as well as malignancies that have spread to the lungs. WP1066, a prominent immune/transcription modulator for the company, is presently in Phase I studies, targeting both adult and pediatric brain tumors, pancreatic cancer, and other types of aggressive malignancies. Further, the firm is developing WP1220, an analog of WP1066, intended for topical application in treating cutaneous T-cell lymphoma. Another compound, WP1122, is under development for glioblastoma multiforme and COVID-19. Moleculin Biotech has established collaboration agreements and partnerships with organizations such as MD Anderson, Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o. The company was founded in 2015 and maintains its principal offices in Houston, Texas.
Hisse Fiyatı
$0.6155
Son senkronizasyon: 2026-08-14
Piyasa Değeri
$3.28M
Değişim (1 gün)
7.74%
Değişim (1 yıl)
-96.39%
Ülke
US
Ticaret Moleculin Biotech, Inc. (MBRX)

Kategori

Moleculin Biotech, Inc. (MBRX) için gelir
Aug 2026 itibarıyla gelir TTM: 0
Moleculin Biotech, Inc. şirketinin en son finansal raporlarına göre, mevcut geliri (TTM) 0'dir. 2026 yılında şirketin geliri 0 önceki yıla eşit 2026 yılındaki 0 gelirine göre. Gelir, bir şirketin mal veya hizmet satışından elde ettiği toplam tutardır. Kazançtan farklı olarak, hiçbir gider düşülmez.
Moleculin Biotech, Inc. için 2026 ile 2026 arasındaki gelir geçmişi
Her yılın sonunda gelir
Yıl Gelir Değiştir
Sağlanan tarihler için yeterli veri yok.
Benzer şirketler veya rakiplerin geliri
Şirket Gelir Gelir Farkı Ülke
$12.62B -
US
$6.02B -
NL
- -
CH
- -
KR
$10.11B -
BE